Clinical trial
Complementary Testing to Evaluate Immunogenicity of Human Papillomavirus (HPV)…
NCT00456807 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00456807 |
|---|---|
| Title | Complementary Testing to Evaluate Immunogenicity of Human Papillomavirus (HPV) Vaccine (580299) in Healthy Female Subjects Aged >/= 26 Years |
| Official title | Complementary Testing to Further Evaluate the Immunogenicity of a GSK Biologicals' HPV Vaccine (580299) in Healthy Female Subjects Aged Over 26 Years Enrolled in Study 104820. |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Infections, Papillomavirus |
| Intervention type | Biological |
| Interventions | Placebo, Cervarix TM |
| Enrollment | 100 |
| Start date | Apr 1, 2007 |
| Primary completion | Jan 1, 2008 |
| Completion | Jan 1, 2008 |
| First posted | Apr 5, 2007 |
| Last update posted | Dec 16, 2016 |
| Countries | Netherlands |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: